Limitations of Aptamers

Aptamers are short chains of nucleic or amino acids that are complementary to a specific target molecule and, hence, bind only with that molecule. This means that they are frequently DNA or RNA segments (oligonucleotides), or even peptides. Aptamers are often used in biological research or for clinical applications as ligands, probes, and biosensors.

Aptamers are short chains of nucleic or amino acids that are complementary to a specific target molecule and, hence, bind only with that molecule.molekuul_be | Shutterstock

How are aptamers currently used?

Aptamers are highly effective probes in research, and they are known to provide greater specificity than antibodies in many cases. Western blots and enzyme-linked immunosorbent assays are good examples of applications where aptamers are highly valued for their specificity. Aptamers can also be used to purify proteins.

Aptamers are as much as 100 times smaller than antibodies, and thus can be used in smaller volume systems with a greater density of recognition units. Furthermore, aptamers can be conjugated to drugs or fluorescent probes as targeting ligands, providing highly specific delivery systems.

What are the main limitations of aptamers?

Aptamers, particularly RNA strands, are prone to quick degradation in biological media due to interactions with biomolecules. Many aptamers have been shown to degrade in blood as quickly as a few minutes, which is far too short for most medical applications.

Accordingly, chemical modifications of aptamers have been performed to improve their half-life in circulation in vivo. The incorporation of polyethylene glycol (PEG) ligands or modification of 3’ and 5’-termini provides resistance to exonucleases.

Since most aptamers are relatively small molecules of only 5 to 15 kilodaltons (kDa), they are easily removed by the kidneys and excreted from the body. Conjugation with large PEG ligands that increase the molecular weight above around 40 kDa reduce the occurrence of excretion via the kidneys.

How to control aptamers in the body?

The pharamacokinetic properties of aptamers are also relatively difficult to control, as they may degrade, be excreted, or be involved in metabolic processes at different rates throughout the body. These factors strongly affect the duration of action of an aptamer drug, biosensor or probe, which is of critical importance in a clinical setting.

Complimentary aptamers to the aptamer are used as an ‘antidote’ to remove excess aptamers still present in the body after the desired function has been performed. Once the aptamer-antidote hybrid is formed within the body it renders the aptamer inert, and it is then subject to regular excretion through the kidneys.

Aptamers mostly target molecules on the surface of cells or that are present in the blood stream, as they have difficulty entering cells and finding intra-cellular targets without the aid of a cell-penetrating component. Recombinant vectors that enter cells and then express the aptamer have been developed, overcoming the problem of cell penetration (since the aptamer is generated within the cell to begin with).

Issues with creating aptamers

Aptamers are usually created using target molecules that must be highly accurate and pure. This is a highly labor intensive and costly process, with some additional difficulties caused by different protein structure when located in the natural environment of the cell due to post-translational modifications.

Systematic evolution of ligands by exponential enrichment (SELEX) is one method used to attempt to overcome this limitation by using in vitro selection of aptamers in living cells. More specifically,  the proteins are then in the correct state to interact with the aptamers.

Although highly specific, it is also possible for aptamers to interact with the incorrect target in vivo. SELEX is also used to overcome this issue by using a negative selection step and improving the selectivity of the aptamer.

Further Reading

Last Updated: Mar 27, 2019

Michael Greenwood

Written by

Michael Greenwood

Michael graduated from Manchester Metropolitan University with a B.Sc. in Chemistry in 2014, where he majored in organic, inorganic, physical and analytical chemistry. He is currently completing a Ph.D. on the design and production of gold nanoparticles able to act as multimodal anticancer agents, being both drug delivery platforms and radiation dose enhancers.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Greenwood, Michael. (2019, March 27). Limitations of Aptamers. News-Medical. Retrieved on May 15, 2021 from

  • MLA

    Greenwood, Michael. "Limitations of Aptamers". News-Medical. 15 May 2021. <>.

  • Chicago

    Greenwood, Michael. "Limitations of Aptamers". News-Medical. (accessed May 15, 2021).

  • Harvard

    Greenwood, Michael. 2019. Limitations of Aptamers. News-Medical, viewed 15 May 2021,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.